Imfinzi Shows Significant Survival Benefit in Phase 3 Trial for Non-Small Cell Lung Cancer
September 10th 2021Results from POSEIDON, a randomized open label, phase 3 trial, showed that patients administered 5 cycles of tremelimumab plus durvalumab and chemotherapy over 16 weeks experienced a 23% reduction in the risk of death compared with various chemotherapy options.
Read More
PQA-Supported Research Examines Cost Barriers to Medication Access and Adherence
September 10th 2021The Pharmacy Quality Alliance developed the “Medication Access Framework for Quality Measurement” to address the social determinants of health that hinder patient medication access and contribute to poor health outcomes.
Read More
Study: Lung Function Unaffected After COVID-19 Infection in Young Adults
September 8th 2021The investigators said that even patients with asthma showed no statistically significant deterioration in lung function, although there was a trend toward slightly lower measurements for the amount of air they could exhale forcibly in 1 second.
Read More
Study Identifies New Risk Factors for Certain Bleeding Complications Following Myocardial Infarction
September 8th 2021Bleeding in the upper GI tract is among the most common bleeding complications following acute myocardial infarction, causing considerable suffering and increasing the risk of death.
Read More
Study Identifies How PARP Inhibitors Fight BRCA1, BRCA2 Tumor Cells
September 8th 2021This drug class works by interfering with the ability of cancer cells to repair themselves after experiencing damage to their DNA, but how PARP inhibitors selectively kill cancer cells was previously unknown.
Read More